Abstract
The objective is to assess the effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Male Wistar rats, 8-week-old, were categorized into four groups, which were the control (n = 9), diabetes (n = 9), infliximab-treated diabetes (n = 10), and FR167653-treated diabetes (n = 9) groups. Diabetes was induced by intraperitoneal injection of STZ (40 mg/kg). Thereafter, infliximab was injected intraperitoneally once a month (5.5 mg/kg) and FR167653 was administered orally by mixing with the rat chow (0.08%). The effects of infliximab and FR167653 on urinary albumin excretion were observed for 12 weeks. Body weight, blood sugar, 24-h urinary TNF-α, and 24-h urinary albumin/creatinine ratio (Ualb/Ucr) levels were determined at 1, 4, 8, and 12 weeks after the STZ-injection. Treatment of rats with STZ caused a significant loss of body weight, as well as polyuria and hyperglycemia within 1 week, while the urinary excretions of albumin and TNF-α were increased. Neither infliximab nor FR167653 affected body weight or blood sugar levels, whereas both decreased urinary albumin excretion, together with a modest decrease in the urinary excretion of TNF-α. These results suggest a role of TNF-α in the pathogenesis of diabetic nephropathy and show that TNF-α inhibition is a potential therapeutic strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hasegawa G, Nakano K, Sawada M et al (1991) Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012
Shikano M, Sobajima H, Yoshikawa H et al (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85:81–85
Moriwaki Y, Yamamoto T, Shibutani Y et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608
Kalantarinia K, Awad AS, Siragy HM (2003) Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64:1208–1213
Navarro J, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor alpha in diabetic patients with advanced renal failure: effects of pentoxifyline administration. Am J Kidney Dis 33:458–463
Navarro JF, Milena FJ, Mora C et al (2005) Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 99:S98–S102
Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563
Baert FJ, D’Haens GR, Peeters M et al (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28
Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M (1996) Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 314:137–142
Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, Okuhara M (1997) FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 327:169–174
Ando T, Kurita S, Takamura T (2004) The specific p38 mitogen-activated protein kinase pathway inhibitor FR167653 keeps insulitis benign in nonobese diabetic mice. Life Sci 74:1817–1827
Olmarker K, Nutu M, Storkson R (2003) Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 28:1635–1642
Koshikawa M, Mukoyama M, Mori K et al (2005) Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690–2701
Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187:447–463
Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121
Sugimoto H, Shikata K, Wada J et al (1999) Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42:878–886
Nakamura T, Fukui M, Ebihara I et al (1993) mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450–456
Dipetrillo K, Gesek FA (2004) Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24:352–359
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moriwaki, Y., Inokuchi, T., Yamamoto, A. et al. Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44, 215–218 (2007). https://doi.org/10.1007/s00592-007-0007-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-007-0007-6